Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 1
2005 2
2006 1
2007 2
2008 1
2009 1
2010 4
2011 6
2012 8
2013 9
2014 14
2015 12
2016 10
2017 6
2018 7
2019 6
2020 12
2021 9
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year
Filters applied: . Clear all
Page 1
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC, Gilan O, Jackson S, Tan L, Wong SQ, Hollizeck S, Michalak EM, Siddle HV, McCabe MT, Prinjha RK, Guerra GR, Solomon BJ, Sandhu S, Dawson SJ, Beavis PA, Tothill RW, Cullinane C, Lehner PJ, Sutherland KD, Dawson MA. Burr ML, et al. Among authors: cullinane c. Cancer Cell. 2019 Oct 14;36(4):385-401.e8. doi: 10.1016/j.ccell.2019.08.008. Epub 2019 Sep 26. Cancer Cell. 2019. PMID: 31564637 Free PMC article.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE. AbuHammad S, et al. Among authors: cullinane c. Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22. Proc Natl Acad Sci U S A. 2019. PMID: 31439820 Free PMC article.
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
Lelliott EJ, Mangiola S, Ramsbottom KM, Zethoven M, Lim L, Lau PKH, Oliver AJ, Martelotto LG, Kirby L, Martin C, Patel RP, Slater A, Cullinane C, Papenfuss AT, Haynes NM, McArthur GA, Oliaro J, Sheppard KE. Lelliott EJ, et al. Among authors: cullinane c. Cancer Immunol Res. 2021 Feb;9(2):136-146. doi: 10.1158/2326-6066.CIR-20-0401. Epub 2020 Dec 10. Cancer Immunol Res. 2021. PMID: 33303574
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study.
Michael M, Liauw W, McLachlan SA, Link E, Matera A, Thompson M, Jefford M, Hicks RJ, Cullinane C, Hatzimihalis A, Campbell IG, Rowley S, Beale PJ, Karapetis CS, Price T, Burge ME. Michael M, et al. Among authors: cullinane c. Cancer Chemother Pharmacol. 2021 Jul;88(1):39-52. doi: 10.1007/s00280-021-04264-8. Epub 2021 Mar 23. Cancer Chemother Pharmacol. 2021. PMID: 33755789
Imaging Somatostatin Positive Tumors with Tyr3-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68.
Noor A, Van Zuylekom JK, Rudd SE, Roselt PD, Haskali MB, Yan E, Wheatcroft M, Hicks RJ, Cullinane C, Donnelly PS. Noor A, et al. Among authors: cullinane c. Bioconjug Chem. 2021 Jul 21;32(7):1192-1203. doi: 10.1021/acs.bioconjchem.1c00109. Epub 2021 Mar 31. Bioconjug Chem. 2021. PMID: 33788556
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
Kusnadi EP, Trigos AS, Cullinane C, Goode DL, Larsson O, Devlin JR, Chan KT, De Souza DP, McConville MJ, McArthur GA, Thomas G, Sanij E, Poortinga G, Hannan RD, Hannan KM, Kang J, Pearson RB. Kusnadi EP, et al. Among authors: cullinane c. EMBO J. 2020 Nov 2;39(21):e105111. doi: 10.15252/embj.2020105111. Epub 2020 Sep 18. EMBO J. 2020. PMID: 32945574 Free PMC article.
102 results